Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 20;20(5):14.
doi: 10.1007/s11892-020-01297-w.

"H" for Heterogeneity in the Algorithm for Type 2 Diabetes Management

Pieralice Silvia  1 , Zampetti Simona  2 , Maddaloni Ernesto  3 , Buzzetti Raffaella  2
Affiliations
Review

"H" for Heterogeneity in the Algorithm for Type 2 Diabetes Management

Pieralice Silvia et al. Curr Diab Rep. .

Erratum in

Abstract

Purpose of review: Genetic, socioeconomic and clinical features vary considerably among individuals with type 2 diabetes (T2D) influencing disease development, progression and response to therapy. Although a patient-centred approach to pharmacologic therapy of T2D is widely recommended, patients are often treated similarly, irrespective of the differences that may affect therapeutic response. Addressing the heterogeneity of T2D is a major task of diabetes research to lower the high rate of treatment failure as well as to reduce the risk of long-term complications.

Recent findings: A pathophysiology-based clustering system seems the most promising to help in the stratification of diabetes in terms of complication risk and response to treatment. This urges for clinical studies looking at novel biomarkers related to the different metabolic pathways of T2D and able to inform about the therapeutic cluster of each patient. Here, we review the main settings of diabetes heterogeneity, to what extent it has been already addressed and the current gaps in knowledge towards a personalized therapeutic approach that considers the distinctive features of each patient.

Keywords: Diabetes; Heterogeneity; Hypoglycemic drugs; Therapeutic algorithm; Type 2 diabetes.

PubMed Disclaimer

References

    1. Diabetes Metab Res Rev. 2016 Feb;32(2):169-75 - PubMed
    1. Hum Mol Genet. 2012 Jul 1;21(13):3042-9 - PubMed
    1. Nat Genet. 2006 Mar;38(3):320-3 - PubMed
    1. Nutr Metab (Lond). 2018 Jun 28;15:47 - PubMed
    1. FEBS Lett. 2010 Aug 20;584(16):3592-600 - PubMed

MeSH terms

LinkOut - more resources